GlassScriptPhysician profile
Alejandro Daniel Perez Trepichio
NPI 1487605622
$5,839.88
in general payments reported to CMS, 2019-2025
28 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,714 · 2020: $827 · 2021: $420 · 2022: $376 · 2023: $248 · 2024: $72.81 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,245.81 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $932.95 | 2019-2023 | Rybelsus, Tresiba, Ozempic |
| Astrazeneca Pharmaceuticals LP | $477.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.93 | 2019-2020 | |
| Pfizer INC. | $377.51 | 2019-2024 | |
| Amgen INC. | $304.51 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $294.48 | 2019-2022 | |
| Astellas Pharma US INC | $278.98 | 2019-2022 | |
| Amarin Pharma, INC. | $217.89 | 2019-2020 | |
| Glaxosmithkline, LLC. | $190.21 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $174.00 | 2019 | |
| Abbott Laboratories | $163.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $160.82 | 2019-2020 | |
| Sanofi Pasteur INC. | $139.28 | 2019-2023 | |
| Intuitive Surgical, INC. | $128.00 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.99 | 2019-2020 | |
| Arthrex, INC. | $45.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $35.83 | 2019-2020 | |
| Boston Scientific Corporation | $33.27 | 2024 | Watchman Flx |
| Dexcom, INC. | $20.33 | 2025 | Dexcom G6 Transmitter |
| Axonics, INC. | $18.17 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.15 | 2020 | |
| Cvrx, INC. | $17.03 | 2025 | Barostim Neo System |
| Corcept Therapeutics | $16.45 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.41 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.60 | 2019 | |
| Seqirus USA INC | $14.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Perez Trepichio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.